Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

帕洛诺塞隆 格拉司琼 医学 昂丹司琼 恶心 地塞米松 呕吐 化疗 化疗引起恶心呕吐 麻醉 止吐药 内科学
作者
Mitsue Saito,Kenjiro Aogi,Ikuo Sekine,Hirohisa Yoshizawa,Yasuhiro Yanagita,Hiroshi Sakai,Kenichi Inoue,Chiyoe Kitagawa,Takashi Ogura,Shoichi Mitsuhashi
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:10 (2): 115-124 被引量:430
标识
DOI:10.1016/s1470-2045(08)70313-9
摘要

Background Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT3)-receptor antagonist that has shown better efficacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar efficacy to ondansetron in preventing CINV in patients receiving highly emetogenic chemotherapy. In this phase III, multicentre, randomised, double-blind, double-dummy, stratified, parallel-group, active-comparator trial, we assessed the efficacy and safety of palonosetron versus granisetron for chemotherapy-induced nausea and vomiting, both of which were administered with dexamethasone in patients receiving highly emetogenic chemotherapy. Methods Between July 5, 2006, and May 31, 2007, 1143 patients with cancer who were receiving highly emetogenic chemotherapy (ie, cisplatin, or an anthracycline and cyclophosphamide combination [AC/EC]) were recruited from 75 institutions in Japan, and randomly assigned to either single-dose palonosetron (0·75 mg), or granisetron (40 μg/kg) 30 min before chemotherapy on day 1, both with dexamethasone (16 mg intravenously) on day 1 followed by additional doses (8 mg intravenously for patients receiving cisplatin or 4 mg orally for patients receiving AC/EC) on days 2 and 3. A non-deterministic minimisation method with a stochastic-biased coin was applied to the randomisation of patients. Covariates known to effect emetic risk, such as sex, age, and type of highly emetogenic chemotherapy, were used as stratification factors of minimisation to ensure balance between the treatment groups. Primary endpoints were the proportion of patients with a complete response (defined as no emetic episodes and no rescue medication) during the acute phase (0–24 h postchemotherapy; non-inferiority comparison with granisetron) and the proportion of patients with a complete response during the delayed phase (24–120 h postchemotherapy; superiority comparison with granisetron). The non-inferiority margin was predefined in the study protocol as a 10% difference between groups in the proportion of patients with complete response. The palonosetron dose of 0·75 mg was chosen on the basis of two dose-determining trials in Japanese patients. All patients who received study treatment and highly emetogenic chemotherapy were included in the efficacy analyses (modified intention to treat). This trial is registered with ClinicalTrials.gov, number NCT00359567. Findings 1114 patients were included in the efficacy analyses: 555 patients in the palonosetron group and 559 patients in the granisetron group. 418 of 555 patients (75·3%) in the palonosetron group had complete response during the acute phase compared with 410 of 559 patients (73·3%) in the granisetron group (mean difference 2·9% [95% CI −2·70 to 7·27]). During the delayed phase, 315 of 555 patients (56·8%) had complete response in the palonosetron group compared with 249 of 559 patients (44·5%) in the granisetron group (p<0·0001). The main treatment-related adverse events were constipation (97 of 557 patients [17·4%] in the palonosetron group vs 88 of 562 [15·7%] in the granisetron group) and raised concentrations of serum aminotransferases (aspartate aminotransferase: 24 of 557 [4·3%] vs 34 of 562 [6·0%]; alanine aminotransferase: 16 of 557 [2·9%] vs 33 of 562 [5·9%]); no grade 4 main treatment-related adverse events were reported. Interpretation When administered with dexamethasone before highly emetogenic chemotherapy, palonosetron exerts efficacy against chemotherapy-induced nausea and vomiting which is non-inferior to that of granisetron in the acute phase and better than that of granisetron in the delayed phase, with a comparable safety profile for the two treatments. Funding Taiho Pharmaceutical (Tokyo, Japan).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
丘比特的应助被嗷嗷采纳,获得10
3秒前
3秒前
受伤冰菱完成签到,获得积分10
4秒前
4秒前
领导范儿的应助被YunjiangZhang采纳,获得10
5秒前
乐观迎天关注了科研通微信公众号
5秒前
科研通AI2S的应助被碧蓝小蜜蜂采纳,获得10
5秒前
Jasper的应助被醉熏的寄松采纳,获得10
6秒前
汉堡包的应助被醉熏的寄松采纳,获得10
6秒前
Owen的应助被醉熏的寄松采纳,获得10
6秒前
NexusExplorer的应助被醉熏的寄松采纳,获得10
6秒前
ding的应助被醉熏的寄松采纳,获得10
6秒前
脑洞疼的应助被醉熏的寄松采纳,获得10
7秒前
orixero的应助被醉熏的寄松采纳,获得10
7秒前
老班长完成签到,获得积分10
7秒前
搜集达人的应助被醉熏的寄松采纳,获得10
7秒前
CipherSage的应助被醉熏的寄松采纳,获得10
7秒前
CodeCraft的应助被醉熏的寄松采纳,获得10
7秒前
master发布了新的文献求助10
8秒前
lemonade发布了新的文献求助10
8秒前
LL完成签到 ,获得积分10
9秒前
9秒前
小叶紫檀完成签到,获得积分10
10秒前
10秒前
xiaoxiao发布了新的文献求助10
11秒前
lalala发布了新的文献求助10
11秒前
lulu发布了新的文献求助10
11秒前
11秒前
六六完成签到 ,获得积分10
12秒前
斯文败类的应助被隐形的芹菜采纳,获得10
13秒前
搜集达人的应助被科研通管家采纳,获得10
13秒前
天天快乐的应助被科研通管家采纳,获得10
13秒前
13秒前
14秒前
FashionBoy的应助被科研通管家采纳,获得30
14秒前
14秒前
null的应助被科研通管家采纳,获得10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183414
求助须知:如何正确求助?哪些是违规求助? 9572730
关于积分的说明 21827174
捐赠科研通 7780508
什么是DOI,文献DOI怎么找? 3434008
关于科研通互助平台的介绍 2558183
邀请新用户注册赠送积分活动 2480343